New directions in the management of advanced pancreatic cancer: a review
Complete surgical resection is the only potentially curative option for pancreatic cancer. However, most patients have advanced/metastatic disease at the time of diagnosis, or will relapse after surgery. Systemic chemotherapy is only palliative. Gemcitabine-based therapy is an acceptable standard fo...
Saved in:
| Published in: | Anti-cancer drugs Vol. 19; no. 5; pp. 435 - 446 |
|---|---|
| Main Author: | |
| Format: | Journal Article |
| Language: | English |
| Published: |
England
Lippincott Williams & Wilkins, Inc
01-06-2008
|
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Complete surgical resection is the only potentially curative option for pancreatic cancer. However, most patients have advanced/metastatic disease at the time of diagnosis, or will relapse after surgery. Systemic chemotherapy is only palliative. Gemcitabine-based therapy is an acceptable standard for unresectable locally advanced/metastatic pancreatic cancer, but average median survival is only 6 months. The addition of other chemotherapies (including other antimetabolites, platinum, and topoisomerase I inhibitors) or targeted therapies (farnesyl transferase inhibitors, metalloproteinase inhibitors, cetuximab and bevacizumab) to gemcitabine has failed to improve outcome. The combination of gemcitabine and erlotinib, a small-molecule tyrosine kinase inhibitor of the human epidermal growth factor receptor, was recently approved by the US/European authorities for use in advanced disease. In a phase III trial, the combination demonstrated a significant improvement in overall survival compared with gemcitabine monotherapy. Positive efficacy results have also been observed in a phase III trial, favoring the addition of capecitabine to gemcitabine compared with gemcitabine alone. This review focuses on the recent developments in systemic treatment, and discusses how novel agents might be incorporated into future treatment strategies for pancreatic cancer. |
|---|---|
| AbstractList | Complete surgical resection is the only potentially curative option for pancreatic cancer. However, most patients have advanced/metastatic disease at the time of diagnosis, or will relapse after surgery. Systemic chemotherapy is only palliative. Gemcitabine-based therapy is an acceptable standard for unresectable locally advanced/metastatic pancreatic cancer, but average median survival is only 6 months. The addition of other chemotherapies (including other antimetabolites, platinum, and topoisomerase I inhibitors) or targeted therapies (farnesyl transferase inhibitors, metalloproteinase inhibitors, cetuximab and bevacizumab) to gemcitabine has failed to improve outcome. The combination of gemcitabine and erlotinib, a small-molecule tyrosine kinase inhibitor of the human epidermal growth factor receptor, was recently approved by the US/European authorities for use in advanced disease. In a phase III trial, the combination demonstrated a significant improvement in overall survival compared with gemcitabine monotherapy. Positive efficacy results have also been observed in a phase III trial, favoring the addition of capecitabine to gemcitabine compared with gemcitabine alone. This review focuses on the recent developments in systemic treatment, and discusses how novel agents might be incorporated into future treatment strategies for pancreatic cancer. |
| Author | Rocha-Lima, Caio M |
| AuthorAffiliation | University of Miami Miller School of Medicine and Sylvester Cancer Center, Miami, Florida, USA |
| AuthorAffiliation_xml | – name: University of Miami Miller School of Medicine and Sylvester Cancer Center, Miami, Florida, USA |
| Author_xml | – sequence: 1 givenname: Caio surname: Rocha-Lima middlename: M fullname: Rocha-Lima, Caio M organization: University of Miami Miller School of Medicine and Sylvester Cancer Center, Miami, Florida, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/18418211$$D View this record in MEDLINE/PubMed |
| BookMark | eNpdkM1LAzEQxYMoWqv_gUhO3lZnknR3403qJxS96Dmkyaxd3Y-abFv8741aEDwN83jvMfM7ZLtd3xFjJwjnCLq4mF5dn8McUJIUpaic9og7bISqkNmkULjLRqAnOlO6kAfsMMY3AEi63GcHWCosBeKI3T_Shvs6kBvqvou87viwIN7azr5SS93A-4pbv7adI8-XaQSyQ-24-1bCJbc80LqmzRHbq2wT6Xg7x-zl9uZ5ep_Nnu4eplezzCnMMUun-sIWE1_ZSpCXKAVpjdJKNXcAuYcSpFa5plwIrKyUpJwr5xbUxJdKyjE7--1dhv5jRXEwbR0dNY3tqF9Fk2tEUAKSUf0aXehjDFSZZahbGz4NgvkmaBJB859gip1u-1fzlvxfaIvsr3fTNwOF-N6sNhTMgmwzLExiDFiizASkT_K0ZT-S_AIwpH2H |
| CitedBy_id | crossref_primary_10_1002_jmri_25952 crossref_primary_10_1007_s00280_010_1306_0 crossref_primary_10_1002_ijc_25041 crossref_primary_10_1590_S0102_67202008000400008 crossref_primary_10_1007_s11605_010_1323_7 crossref_primary_10_3748_wjg_v21_i12_3579 crossref_primary_10_1016_j_surg_2009_04_015 crossref_primary_10_1517_14728210902972502 crossref_primary_10_1586_ecp_09_30 crossref_primary_10_23736_S0394_9508_18_04824_6 crossref_primary_10_1007_s00384_010_0946_1 crossref_primary_10_1097_MCG_0b013e31829f56e7 crossref_primary_10_1007_s00280_010_1343_8 crossref_primary_10_1186_1471_2407_10_86 crossref_primary_10_18632_oncotarget_7537 crossref_primary_10_1211_jpp_61_08_0010 crossref_primary_10_1016_j_soncn_2008_10_006 crossref_primary_10_1038_nrgastro_2010_98 crossref_primary_10_1007_s13193_012_0189_4 crossref_primary_10_7759_cureus_39660 crossref_primary_10_1007_s00280_009_1095_5 crossref_primary_10_1186_1475_2891_11_52 crossref_primary_10_2478_v10042_010_0057_4 crossref_primary_10_1016_j_surg_2018_05_040 crossref_primary_10_3748_wjg_v21_i21_6582 crossref_primary_10_1021_mp9002317 crossref_primary_10_1517_14728222_12_11_1389 crossref_primary_10_1007_s10330_016_0163_7 crossref_primary_10_1016_j_canlet_2011_11_029 crossref_primary_10_1021_acs_biochem_6b00450 crossref_primary_10_1111_j_1476_5381_2012_01873_x |
| Cites_doi | 10.1200/JCO.2005.01.9661 10.1002/1097-0142(19950415)75:8<2069::AID-CNCR2820750807>3.0.CO;2-7 10.1200/JCO.2002.11.149 10.1200/JCO.2004.12.082 10.1200/JCO.2004.08.158 10.1200/JCO.2005.02.840 10.1200/JCO.1992.10.3.406 10.1093/annonc/mdi309 10.1002/(SICI)1097-0142(20000515)88:10<2239::AID-CNCR6>3.0.CO;2-V 10.1016/S0093-7754(03)00273-2 10.1097/00000658-199501000-00007 10.1126/science.1099314 10.1016/S1470-2045(05)70175-3 10.1007/s00280-006-0389-0 10.3816/CLC.2006.n.022 10.1200/JCO.1985.3.3.373 10.1093/annonc/mdh065 10.1056/NEJMoa050753 10.1158/1078-0432.CCR-040012 10.1097/00006676-200208000-00002 10.1016/S0039-6060(97)90128-8 10.1200/JCO.2003.09.140 10.1056/NEJMoa040938 10.1016/S0399-8320(06)73157-8 10.1200/JCO.2005.06.023 10.1200/JCO.2005.02.477 10.1001/archsurg.1985.01390320023003 10.1016/1040-8428(94)00144-I 10.1002/1097-0142(19811015)48:8<1705::AID-CNCR2820480803>3.0.CO;2-4 10.1073/pnas.0405220101 10.1200/JCO.2004.10.112 10.1200/JCO.1991.9.3.491 10.1385/IJGC:25:2:89 10.1309/5CWPU41AFR1VYM3F 10.1200/JCO.2001.19.15.3447 10.1200/JCO.2006.07.9525 10.1200/JCO.2003.10.038 10.1093/jnci/djh217 10.1016/S0140-6736(04)15841-8 10.1158/1078-0432.CCR-040007 10.1200/JCO.2006.09.0886 10.1053/hupa.2001.28959 10.1016/S0093-7754(03)70010-4 10.1056/NEJMoa050736 10.1093/annonc/mdm283 10.1016/S0959-8049(01)00231-3 10.1097/00000658-199912000-00006 10.1007/s10434-001-0758-1 10.1053/sonc.2002.35645 10.1016/S1040-8428(02)00015-X 10.1073/pnas.80.5.1337 10.1200/JCO.2002.20.1.160 10.3322/canjclin.55.2.74 10.1200/JCO.2005.00.6916 10.1056/NEJMoa032295 10.1200/JCO.2005.05.1474 10.1200/JCO.2004.12.040 10.1200/JCO.1997.15.6.2403 10.1001/jama.297.3.267 10.1200/JCO.2006.07.0201 10.1038/sj.bjc.6600446 10.1200/JCO.2003.02.098 10.1016/S0959-8049(98)00069-0 |
| ContentType | Journal Article |
| Copyright | 2008 Lippincott Williams & Wilkins, Inc. |
| Copyright_xml | – notice: 2008 Lippincott Williams & Wilkins, Inc. |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
| DOI | 10.1097/CAD.0b013e3282fc9d11 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1473-5741 |
| EndPage | 446 |
| ExternalDocumentID | 10_1097_CAD_0b013e3282fc9d11 18418211 00001813-200806000-00001 |
| Genre | Journal Article Review |
| GroupedDBID | - .XZ .Z2 0R 23M 4Q1 4Q2 4Q3 53G 5GY 5VS 71W 8L- AAMTA AAPBV AARTV AAYEP ABBUW ABXVJ ABZAD ACDDN ACEWG ACGFS ACWDW ACWRI ACXNZ ADFPA ADNKB AE3 AENEX AHULI AHVBC AJIOK AJNYG ALMA_UNASSIGNED_HOLDINGS AMJPA ASCII AWKKM BQLVK C45 CAG COF CS3 DUNZO E.X EBS EJD EX3 F5P FL- H0 H0~ HZ IN IN~ JF9 JG8 JK3 JK8 K8S KD2 L-C N9A N~M O9- OAG OAH OCUKA ODA OHASI OLG OLW OPUJH ORVUJ OUVQU OVD OVDNE OWW OWY OXXIT P-K R58 RIG RLZ RSW S4R S4S UDS V2I WOQ WOW X3V X3W XZ Z2 --- .-D 0R~ 6J9 AAAAV AAHPQ AAIQE AASCR ABASU ABDIG ABJNI ABVCZ ACILI ACXJB ADGGA ADHPY AE6 AEETU AFDTB AGINI AHQNM AINUH AJNWD AJZMW ALMTX AMKUR AMNEI AOHHW BS7 CGR CUY CVF DIWNM ECM EEVPB EIF FCALG GNXGY GQDEL HLJTE HZ~ IKREB IPNFZ NPM OPC OWU OWV OWX OWZ T8P TEORI TSPGW VVN W3M XXN XYM YFH ZFV ZZMQN AAYXX CITATION 7X8 |
| ID | FETCH-LOGICAL-c4161-282d7a75dfaf2ed3132e9913a34bc006d08039469e6221fa33e4cc8ba045d8433 |
| ISSN | 0959-4973 |
| IngestDate | Fri Aug 16 07:28:32 EDT 2024 Fri Aug 23 03:17:18 EDT 2024 Sat Sep 28 07:57:24 EDT 2024 Thu Aug 13 19:50:10 EDT 2020 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Language | English |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c4161-282d7a75dfaf2ed3132e9913a34bc006d08039469e6221fa33e4cc8ba045d8433 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
| PMID | 18418211 |
| PQID | 69110420 |
| PQPubID | 23479 |
| PageCount | 12 |
| ParticipantIDs | proquest_miscellaneous_69110420 crossref_primary_10_1097_CAD_0b013e3282fc9d11 pubmed_primary_18418211 wolterskluwer_health_00001813-200806000-00001 |
| ProviderPackageCode | L-C C45 AARTV ADFPA ASCII OLG ODA ABZAD ABBUW JK3 ADNKB JK8 H0~ 8L- JG8 OLW OHASI AHVBC AJNYG FL- K8S AJIOK OPUJH V2I .XZ S4R S4S 4Q1 DUNZO OAG 4Q2 OVDNE 4Q3 AMJPA OAH OVD 71W AHULI ACEWG .Z2 AWKKM OUVQU ORVUJ X3V X3W ACDDN ACWRI AAMTA E.X OWW OCUKA OWY ACXNZ ABXVJ IN~ KD2 OXXIT ACWDW JF9 |
| PublicationCentury | 2000 |
| PublicationDate | 2008-June 2008-Jun 2008-06-00 20080601 |
| PublicationDateYYYYMMDD | 2008-06-01 |
| PublicationDate_xml | – month: 06 year: 2008 text: 2008-June |
| PublicationDecade | 2000 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Anti-cancer drugs |
| PublicationTitleAlternate | Anticancer Drugs |
| PublicationYear | 2008 |
| Publisher | Lippincott Williams & Wilkins, Inc |
| Publisher_xml | – name: Lippincott Williams & Wilkins, Inc |
| References | Abbruzzese (R26-1-20210203) 1991; 9 Ross (R41-1-20210203) 2004; 122 Klinkenbijl (R14-1-20210203) 1999; 230 Neoptolemos (R15-1-20210203) 2004; 350 Bramhall (R34-1-20210203) 2001; 19 Li (R3-1-20210203) 2004; 363 Bruns (R88-1-20210203) 2000; 6 Bruns (R96-1-20210203) 2000; 60 Berlin (R28-1-20210203) 2002; 20 Scagliotti (R56-1-20210203) 2004; 10 Kindler (R46-1-20210203) 2005; 23 Srivastava (R52-1-20210203) 2001; 32 Itakura (R94-1-20210203) 1997; 3 Stathopoulos (R100-1-20210203) 2004; 15 Burris (R22-1-20210203) 1997; 15 (R19-1-20210203) 1988; 80 Moertel (R18-1-20210203) 1981; 48 Salomon (R49-1-20210203) 1995; 19 Fujimoto (R92-1-20210203) 1998; 34 Shepherd (R74-1-20210203) 2005; 353 Moore (R45-1-20210203) 2007; 25 Bramhall (R35-1-20210203) 2002; 87 Clark (R64-1-20210203) 2006; 7 Cappuzzo (R70-1-20210203) 2004; 96 Nicholson (R54-1-20210203) 2001; 37 Birk (R53-1-20210203) 1999; 25 Parkin (R1-1-20210203) 2005; 55 Tsai (R8-1-20210203) 2003; 30 Seo (R91-1-20210203) 2000; 88 Pao (R77-1-20210203) 2004; 101 Petit (R97-1-20210203) 1997; 151 Paez (R76-1-20210203) 2004; 304 Herrmann (R105-1-20210203) 2007; 25 Arteaga (R57-1-20210203) 2003; 30 Rocha Lima (R29-1-20210203) 2004; 22 Klaassen (R20-1-20210203) 1985; 3 Grunewald (R25-1-20210203) 1992; 10 White (R11-1-20210203) 2001; 8 Herbst (R83-1-20210203) 2005; 23 Xiong (R55-1-20210203) 2002; 29 Gatzemeier (R82-1-20210203) 2007; 25 Cartwright (R103-1-20210203) 2002; 20 Allema (R6-1-20210203) 1995; 75 Xiong (R47-1-20210203) 2004; 22 Miller (R61-1-20210203) 2004; 22 Tobita (R50-1-20210203) 2003; 11 Oettle (R31-1-20210203) 2005; 16 Abou-Alfa (R32-1-20210203) 2006; 24 Ng (R59-1-20210203) 2002; 1 Herbst (R98-1-20210203) 2005; 23 Perez-Soler (R84-1-20210203) 2005; 23 Adhoute (R9-1-20210203) 2006; 30 Fukuoka (R62-1-20210203) 2003; 21 Kalser (R12-1-20210203) 1985; 120 Van Cutsem (R33-1-20210203) 2004; 22 Heinemann (R39-1-20210203) 2007; 18 (R13-1-20210203) 1987; 59 Chau (R42-1-20210203) 2003; 45 Plunkett (R24-1-20210203) 1996; 23 Nitecki (R4-1-20210203) 1995; 221 Gandara (R71-1-20210203) 2004; 10 Louvet (R30-1-20210203) 2005; 23 Moore (R36-1-20210203) 2003; 21 Niedergethmann (R93-1-20210203) 2002; 25 Lynch (R75-1-20210203) 2004; 350 Oettle (R16-1-20210203) 2007; 297 Fjallskog (R51-1-20210203) 2003; 9 Tsao (R65-1-20210203) 2005; 353 Tempero (R27-1-20210203) 2003; 21 Arteaga (R58-1-20210203) 2001; 19 Dragovich (R60-1-20210203) 2007; 60 Kawamoto (R85-1-20210203) 1983; 80 Mosca (R5-1-20210203) 1997; 122 Reni (R106-1-20210203) 2005; 6 |
| References_xml | – volume: 23 start-page: 8033 year: 2005 ident: R46-1-20210203 article-title: Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2005.01.9661 contributor: fullname: Kindler – volume: 75 start-page: 2069 year: 1995 ident: R6-1-20210203 article-title: Prognostic factors for survival after pancreaticoduodenectomy for patients with carcinoma of the pancreatic head region publication-title: Cancer doi: 10.1002/1097-0142(19950415)75:8<2069::AID-CNCR2820750807>3.0.CO;2-7 contributor: fullname: Allema – volume: 20 start-page: 3270 year: 2002 ident: R28-1-20210203 article-title: Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297 publication-title: J Clin Oncol doi: 10.1200/JCO.2002.11.149 contributor: fullname: Berlin – volume: 22 start-page: 3776 year: 2004 ident: R29-1-20210203 article-title: Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate publication-title: J Clin Oncol doi: 10.1200/JCO.2004.12.082 contributor: fullname: Rocha Lima – volume: 22 start-page: 1103 year: 2004 ident: R61-1-20210203 article-title: Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2004.08.158 contributor: fullname: Miller – volume: 59 start-page: 2006 year: 1987 ident: R13-1-20210203 article-title: Gastrointestinal Tumor Study Group publication-title: Cancer – volume: 23 start-page: 5892 year: 2005 ident: R83-1-20210203 article-title: TRIBUTE-A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small cell lung cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2005.02.840 contributor: fullname: Herbst – volume: 10 start-page: 406 year: 1992 ident: R25-1-20210203 article-title: Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study publication-title: J Clin Oncol doi: 10.1200/JCO.1992.10.3.406 contributor: fullname: Grunewald – volume: 16 start-page: 1639 year: 2005 ident: R31-1-20210203 article-title: A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer publication-title: Ann Oncol doi: 10.1093/annonc/mdi309 contributor: fullname: Oettle – volume: 1 start-page: 777 year: 2002 ident: R59-1-20210203 article-title: Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma publication-title: Mol Cancer Ther contributor: fullname: Ng – volume: 88 start-page: 2239 year: 2000 ident: R91-1-20210203 article-title: High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma publication-title: Cancer doi: 10.1002/(SICI)1097-0142(20000515)88:10<2239::AID-CNCR6>3.0.CO;2-V contributor: fullname: Seo – volume: 30 start-page: 71 issue: Suppl 9 year: 2003 ident: R8-1-20210203 article-title: Combined modality therapy for pancreatic cancer publication-title: Semin Oncol doi: 10.1016/S0093-7754(03)00273-2 contributor: fullname: Tsai – volume: 221 start-page: 59 year: 1995 ident: R4-1-20210203 article-title: Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? publication-title: Ann Surg doi: 10.1097/00000658-199501000-00007 contributor: fullname: Nitecki – volume: 304 start-page: 1497 year: 2004 ident: R76-1-20210203 article-title: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy publication-title: Science doi: 10.1126/science.1099314 contributor: fullname: Paez – volume: 151 start-page: 1523 year: 1997 ident: R97-1-20210203 article-title: Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors publication-title: Am J Pathol contributor: fullname: Petit – volume: 6 start-page: 369 year: 2005 ident: R106-1-20210203 article-title: Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(05)70175-3 contributor: fullname: Reni – volume: 23 start-page: 3 issue: Suppl year: 1996 ident: R24-1-20210203 article-title: Gemcitabine: preclinical pharmacology and mechanisms of action publication-title: Semin Oncol contributor: fullname: Plunkett – volume: 60 start-page: 295 year: 2007 ident: R60-1-20210203 article-title: Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial publication-title: Cancer Chemother Pharmacol doi: 10.1007/s00280-006-0389-0 contributor: fullname: Dragovich – volume: 7 start-page: 389 year: 2006 ident: R64-1-20210203 article-title: Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21 publication-title: Clin Lung Cancer doi: 10.3816/CLC.2006.n.022 contributor: fullname: Clark – volume: 80 start-page: 751 year: 1988 ident: R19-1-20210203 article-title: Gastrointestinal Tumor Study Group publication-title: J Natl Cancer Inst – volume: 3 start-page: 373 year: 1985 ident: R20-1-20210203 article-title: Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil – an Eastern Cooperative Oncology Group study publication-title: J Clin Oncol doi: 10.1200/JCO.1985.3.3.373 contributor: fullname: Klaassen – volume: 15 start-page: 224 year: 2004 ident: R100-1-20210203 article-title: Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study publication-title: Ann Oncol doi: 10.1093/annonc/mdh065 contributor: fullname: Stathopoulos – volume: 353 start-page: 123 year: 2005 ident: R74-1-20210203 article-title: Erlotinib in previously treated non-small-cell lung cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa050753 contributor: fullname: Shepherd – volume: 10 start-page: 4205s year: 2004 ident: R71-1-20210203 article-title: Bronchioloalveolar carcinoma: a model for investigating the biology of epidermal growth factor receptor inhibition publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-040012 contributor: fullname: Gandara – volume: 25 start-page: 122 year: 2002 ident: R93-1-20210203 article-title: High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas publication-title: Pancreas doi: 10.1097/00006676-200208000-00002 contributor: fullname: Niedergethmann – volume: 3 start-page: 1309 year: 1997 ident: R94-1-20210203 article-title: Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression publication-title: Clin Cancer Res contributor: fullname: Itakura – volume: 122 start-page: 553 year: 1997 ident: R5-1-20210203 article-title: Long-term survival in pancreatic cancer: pylorus-preserving versus Whipple pancreatoduodenectomy publication-title: Surgery doi: 10.1016/S0039-6060(97)90128-8 contributor: fullname: Mosca – volume: 21 start-page: 3402 year: 2003 ident: R27-1-20210203 article-title: Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma publication-title: J Clin Oncol doi: 10.1200/JCO.2003.09.140 contributor: fullname: Tempero – volume: 9 start-page: 1469 year: 2003 ident: R51-1-20210203 article-title: Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors publication-title: Clin Cancer Res contributor: fullname: Fjallskog – volume: 350 start-page: 2129 year: 2004 ident: R75-1-20210203 article-title: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib publication-title: N Engl J Med doi: 10.1056/NEJMoa040938 contributor: fullname: Lynch – volume: 30 start-page: 224 year: 2006 ident: R9-1-20210203 article-title: Subsequent resection of locally advanced pancreatic carcinoma after chemoradiotherapy publication-title: Gastroenterol Clin Biol doi: 10.1016/S0399-8320(06)73157-8 contributor: fullname: Adhoute – volume: 23 start-page: 3509 year: 2005 ident: R30-1-20210203 article-title: Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial publication-title: J Clin Oncol doi: 10.1200/JCO.2005.06.023 contributor: fullname: Louvet – volume: 23 start-page: 2544 year: 2005 ident: R98-1-20210203 article-title: Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2005.02.477 contributor: fullname: Herbst – volume: 120 start-page: 899 year: 1985 ident: R12-1-20210203 article-title: Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection publication-title: Arch Surg doi: 10.1001/archsurg.1985.01390320023003 contributor: fullname: Kalser – volume: 19 start-page: 183 year: 1995 ident: R49-1-20210203 article-title: Epidermal growth factor-related peptides and their receptors in human malignancies publication-title: Crit Rev Oncol Hematol doi: 10.1016/1040-8428(94)00144-I contributor: fullname: Salomon – volume: 48 start-page: 1705 year: 1981 ident: R18-1-20210203 article-title: Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads+5-fluorouracil), and high dose radiation+5-fluorouracil: The Gastrointestinal Tumor Study Group publication-title: Cancer doi: 10.1002/1097-0142(19811015)48:8<1705::AID-CNCR2820480803>3.0.CO;2-4 contributor: fullname: Moertel – volume: 101 start-page: 13306 year: 2004 ident: R77-1-20210203 article-title: EGF receptor gene mutations are common in lung cancers from ‘never smokers’ and are associated with sensitivity of tumors to gefitinib and erlotinib publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0405220101 contributor: fullname: Pao – volume: 22 start-page: 1430 year: 2004 ident: R33-1-20210203 article-title: Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2004.10.112 contributor: fullname: Van Cutsem – volume: 9 start-page: 491 year: 1991 ident: R26-1-20210203 article-title: A phase I clinical, plasma, and cellular pharmacology study of gemcitabine publication-title: J Clin Oncol doi: 10.1200/JCO.1991.9.3.491 contributor: fullname: Abbruzzese – volume: 25 start-page: 89 year: 1999 ident: R53-1-20210203 article-title: Serum and correspondent tissue measurements of epidermal growth factor (EGF) and epidermal growth factor receptor (EGF-R). Clinical relevance in pancreatic cancer and chronic pancreatitis publication-title: Int J Pancreatol doi: 10.1385/IJGC:25:2:89 contributor: fullname: Birk – volume: 122 start-page: 598 year: 2004 ident: R41-1-20210203 article-title: Targeted therapies for cancer 2004 publication-title: Am J Clin Pathol doi: 10.1309/5CWPU41AFR1VYM3F contributor: fullname: Ross – volume: 19 start-page: 3447 year: 2001 ident: R34-1-20210203 article-title: Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial publication-title: J Clin Oncol doi: 10.1200/JCO.2001.19.15.3447 contributor: fullname: Bramhall – volume: 25 start-page: 1960 year: 2007 ident: R45-1-20210203 article-title: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group publication-title: J Clin Oncol doi: 10.1200/JCO.2006.07.9525 contributor: fullname: Moore – volume: 19 start-page: 32S issue: Suppl year: 2001 ident: R58-1-20210203 article-title: The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia publication-title: J Clin Oncol contributor: fullname: Arteaga – volume: 21 start-page: 2237 year: 2003 ident: R62-1-20210203 article-title: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) publication-title: J Clin Oncol doi: 10.1200/JCO.2003.10.038 contributor: fullname: Fukuoka – volume: 96 start-page: 1133 year: 2004 ident: R70-1-20210203 article-title: Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djh217 contributor: fullname: Cappuzzo – volume: 60 start-page: 2926 year: 2000 ident: R96-1-20210203 article-title: Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma publication-title: Cancer Res contributor: fullname: Bruns – volume: 363 start-page: 1049 year: 2004 ident: R3-1-20210203 article-title: Pancreatic cancer publication-title: Lancet doi: 10.1016/S0140-6736(04)15841-8 contributor: fullname: Li – volume: 10 start-page: 4227s issue: 12 year: 2004 ident: R56-1-20210203 article-title: The biology of epidermal growth factor receptor in lung cancer publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-040007 contributor: fullname: Scagliotti – volume: 25 start-page: 2212 year: 2007 ident: R105-1-20210203 article-title: Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group publication-title: J Clin Oncol doi: 10.1200/JCO.2006.09.0886 contributor: fullname: Herrmann – volume: 32 start-page: 1184 year: 2001 ident: R52-1-20210203 article-title: Immunohistochemical expression of transforming growth factor alpha and epidermal growth factor receptor in pancreatic endocrine tumors publication-title: Hum Pathol doi: 10.1053/hupa.2001.28959 contributor: fullname: Srivastava – volume: 30 start-page: 3 issue: Suppl 7 year: 2003 ident: R57-1-20210203 article-title: Targeting HER1/EGFR: a molecular approach to cancer therapy publication-title: Semin Oncol doi: 10.1016/S0093-7754(03)70010-4 contributor: fullname: Arteaga – volume: 11 start-page: 305 year: 2003 ident: R50-1-20210203 article-title: Epidermal growth factor receptor expression in human pancreatic cancer: Significance for liver metastasis publication-title: Int J Mol Med contributor: fullname: Tobita – volume: 353 start-page: 133 year: 2005 ident: R65-1-20210203 article-title: Erlotinib in lung cancer-molecular and clinical predictors of outcome publication-title: N Engl J Med doi: 10.1056/NEJMoa050736 contributor: fullname: Tsao – volume: 18 start-page: 1652 year: 2007 ident: R39-1-20210203 article-title: Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study publication-title: Ann Oncol doi: 10.1093/annonc/mdm283 contributor: fullname: Heinemann – volume: 37 start-page: S9 issue: 4 year: 2001 ident: R54-1-20210203 article-title: EGFR and cancer prognosis publication-title: Eur J Cancer doi: 10.1016/S0959-8049(01)00231-3 contributor: fullname: Nicholson – volume: 230 start-page: 776 year: 1999 ident: R14-1-20210203 article-title: Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group publication-title: Ann Surg doi: 10.1097/00000658-199912000-00006 contributor: fullname: Klinkenbijl – volume: 8 start-page: 758 year: 2001 ident: R11-1-20210203 article-title: Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas publication-title: Ann Surg Oncol doi: 10.1007/s10434-001-0758-1 contributor: fullname: White – volume: 29 start-page: 31 issue: Suppl 14 year: 2002 ident: R55-1-20210203 article-title: Epidermal growth factor receptor-targeted therapy for pancreatic cancer publication-title: Semin Oncol doi: 10.1053/sonc.2002.35645 contributor: fullname: Xiong – volume: 45 start-page: 151 year: 2003 ident: R42-1-20210203 article-title: Matrix metalloproteinase inhibitors: an emphasis on gastrointestinal malignancies publication-title: Crit Rev Oncol Hematol doi: 10.1016/S1040-8428(02)00015-X contributor: fullname: Chau – volume: 80 start-page: 1337 year: 1983 ident: R85-1-20210203 article-title: Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.80.5.1337 contributor: fullname: Kawamoto – volume: 20 start-page: 160 year: 2002 ident: R103-1-20210203 article-title: Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2002.20.1.160 contributor: fullname: Cartwright – volume: 55 start-page: 74 year: 2005 ident: R1-1-20210203 article-title: Global cancer statistics, 2002 publication-title: CA Cancer J Clin doi: 10.3322/canjclin.55.2.74 contributor: fullname: Parkin – volume: 23 start-page: 5235 year: 2005 ident: R84-1-20210203 article-title: Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? publication-title: J Clin Oncol doi: 10.1200/JCO.2005.00.6916 contributor: fullname: Perez-Soler – volume: 350 start-page: 1200 year: 2004 ident: R15-1-20210203 article-title: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa032295 contributor: fullname: Neoptolemos – volume: 25 start-page: 1545 year: 2007 ident: R82-1-20210203 article-title: Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial publication-title: J Clin Oncol doi: 10.1200/JCO.2005.05.1474 contributor: fullname: Gatzemeier – volume: 6 start-page: 1936 year: 2000 ident: R88-1-20210203 article-title: Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms publication-title: Clin Cancer Res contributor: fullname: Bruns – volume: 22 start-page: 2610 year: 2004 ident: R47-1-20210203 article-title: Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial publication-title: J Clin Oncol doi: 10.1200/JCO.2004.12.040 contributor: fullname: Xiong – volume: 15 start-page: 2403 year: 1997 ident: R22-1-20210203 article-title: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial publication-title: J Clin Oncol doi: 10.1200/JCO.1997.15.6.2403 contributor: fullname: Burris – volume: 297 start-page: 267 year: 2007 ident: R16-1-20210203 article-title: Adjuvant chemotherapy with gemcitabine vs. observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial publication-title: JAMA doi: 10.1001/jama.297.3.267 contributor: fullname: Oettle – volume: 24 start-page: 4441 year: 2006 ident: R32-1-20210203 article-title: Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic publication-title: J Clin Oncol doi: 10.1200/JCO.2006.07.0201 contributor: fullname: Abou-Alfa – volume: 87 start-page: 161 year: 2002 ident: R35-1-20210203 article-title: A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer publication-title: Br J Cancer doi: 10.1038/sj.bjc.6600446 contributor: fullname: Bramhall – volume: 21 start-page: 3296 year: 2003 ident: R36-1-20210203 article-title: Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group publication-title: J Clin Oncol doi: 10.1200/JCO.2003.02.098 contributor: fullname: Moore – volume: 34 start-page: 1439 year: 1998 ident: R92-1-20210203 article-title: Expression of two angiogenic factors, vascular endothelial growth factor and platelet-derived endothelial cell growth factor in human pancreatic cancer, and its relationship to angiogenesis publication-title: Eur J Cancer doi: 10.1016/S0959-8049(98)00069-0 contributor: fullname: Fujimoto |
| SSID | ssj0007413 |
| Score | 2.0717185 |
| SecondaryResourceType | review_article |
| Snippet | Complete surgical resection is the only potentially curative option for pancreatic cancer. However, most patients have advanced/metastatic disease at the time... |
| SourceID | proquest crossref pubmed wolterskluwer |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 435 |
| SubjectTerms | Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bevacizumab Capecitabine Cetuximab Chemotherapy, Adjuvant Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Erlotinib Hydrochloride Fluorouracil - administration & dosage Fluorouracil - analogs & derivatives Humans Neoadjuvant Therapy Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - pathology Quinazolines - administration & dosage |
| Title | New directions in the management of advanced pancreatic cancer: a review |
| URI | http://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00001813-200806000-00001 https://www.ncbi.nlm.nih.gov/pubmed/18418211 https://search.proquest.com/docview/69110420 |
| Volume | 19 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1baxQxFA62BbFI0ap1tWoepC82ODPJXOLb0m7ZwlqLTqFvIZNkcJHOyG4X6b_3ZJOZ7LYF9cGXYQhz_zLnlnO-g9B7raJa66witrULYZwawmVliDJJVSlaRXzZ7m38LT-7LI5HbBQaQ4ax_4o0jAHWtnL2H9DuLwoDsA-YwxZQh-1f4W4TFp2e6pLErWl51We5rC38gyhwVqOy2V_KzFzt8ywsGPQ8y9dT4g75oGeLEFz_2qrvkkymV9Klj0xbH1_tIglFyHhaCQky7lqL9NKRr8yCdEXUMUcz4rUmc4HEOwLZE_0Oj7uIK7h4teLaS9g1_uuzL-LkYjIR5eiy3EBbCYgOkFxbw6PTyWmvXcECoo4_0T1rVw7J84_33WXd3LjjQ2yjx79am5Yw_7GsSlixLconaMc7BXjo0HyKHphmFz387NMedtHBuSMYvznEZaiXmx_iA3weqMdvnqExoI8D-njaYEAfB_RxW-MOfRzQxw7aT1hih_1zdHEyKo_GxPfKIMq6qAReWOcyT3Ut68RoS8hpwPSnkrJKgWTV4BlQzjJusiSJa0mpYUoVlQSTXheM0hdos2kb8xJhnYHDlaY5OMZg7pm0qKmm1riOY51UCR8g0n1S8dNRoogulQEgELchGKB33XcXILvsgpRsTLuYiww0LSiNaID2HBzhegUDx9eeS9bwEa46WCwXpYqY2l-_iDJPjxDFr_54r9foUZj7-2jzerYwb9DGXC_e-qn2G80bdJ0 |
| link.rule.ids | 315,782,786,27933,27934,64549,64569,65344,65364 |
| linkProvider | Ovid |
| linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwvV1LT9tAEB61QaJUqFBK2wAte0A-sW3s9RMphygEkhKiSEnV9mTZu2upqmojTIr498x4bVKoOHDpyZZlW9qd2Zlv3gAHSnYypfyU02gX7kZC8yhJNZfaSVMp0k5UjXsbzoLJ9_B4QG1ymlxVKj4rLz7RpRLTdEPjcMgunHe_zKzJ4Nusm1v9Wb_7w5r2TgeVm5qSJKzjbvEnu7J6kyr9CjWXIBYIO35dPE1VXiu-J1y3BSu9_mg8uhPZqFbrmfPVyDXR1NhFwWfckMZZiNZJJiNl2_d12D_A9CWsXxcU6y5_Vanufymsk43_tNRNeFUjWtYzLPganul8C1bP65j9FlhT0x375pDNl8Ve5SGz2HTZN_vmDQxR4DKjYukssJ85Q3TKft8l6LAiY03OAkMpZgCvZJKeXB6xhJlCnG34ejKY94e8HvTAJdlXHDdWBUngqSzJHK2om6RG3CoS4aYSxYLCpYkIDXntO46dJUJoV8owTRCPqtAV4i208iLX74EpH60FzwvQqkOsor0wE0oQMrRt5aRO1AbekC6-MP084iYOj6SOH5K6DfsNfWM8eBRNSXJdLMrYRzWBEq_ThneG7Mv_hS5abfQtv8cHsSltjR-j2c4T39-HF8P5-TgejyZnu7BmMlnIP7QHravLhf4Az0u1-Fgz-y3auwSj |
| linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwvV1Lb9NAEB6VVqpAFYXyaEqhe0A-dUvsdfxA8iHKgwSKFSlBtCfL3l1LCGFXddMq_74zXruhRRy4cLJl2ZZ2Z3bmmzfAeyW7uVJexmm0C3dDoXmYZppL7WSZFFk3rMe9TeZ-fBYMR9Qmp43gU_FZdXFCl1pM0w2NwyG7cBF9nluD-SA6t-LR93kUW7P-p1HtpqYkCWs2HEcraxiV1_mV1Y_rJCzUX4IYIeh6TQk11XptURsrPAJb_cH0dHonuFG5NpPn68Froq20C_0PuC2tyxBtlFyGyrbva7I_4OkT2LkpKeJd_awT3n9TW-Pd_7rgZ_C0Qbesb9jxOWzoYg-2vzbx-z2wZqZT9uqYLdaFX9Uxs9hs3UN79QImKHyZUbd0LtiPgiFSZb_uknVYmbM2f4GhRDPgVzJJTy4_spSZopyX8G08WgwmvBn6wCXZWhy3V_mp31N5mjtaUWdJjRhWpMLNJIoIhUsTIRr12nMcO0-F0K6UQZYiNlWBK8Qr2CzKQu8DUx5aDr2ejxYe4hbdC3KhBKFE21ZO5oQd4C0BkwvT2yNpY_JI8OQhwTtw1FI5wUNIkZW00OWySjxUGSj9uh14bYi__l_gogVH3_J73JCYMtfkbzQ7-Mf3j2Ab2SE5ncZf3sBjk9RCrqJD2Ly6XOq38KhSy3cNx98CptoHhQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=New+directions+in+the+management+of+advanced+pancreatic+cancer%3A+a+review&rft.jtitle=Anti-cancer+drugs&rft.au=Rocha-Lima%2C+Caio+M&rft.date=2008-06-01&rft.issn=0959-4973&rft.volume=19&rft.issue=5&rft.spage=435&rft.epage=446&rft_id=info:doi/10.1097%2FCAD.0b013e3282fc9d11&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0959-4973&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0959-4973&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0959-4973&client=summon |